Diabetes drug exenatide under scrutiny for cancer link

NCT ID NCT05663515

Recruiting now Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 05, 2026 · Updated 3 times

Summary

This study is checking if the diabetes medicine exenatide (Byetta, Bydureon) increases the risk of pancreatic cancer. Researchers will look at health records from 24,000 patients across seven European countries, comparing those who started exenatide with those who started other diabetes drugs. The goal is to see if there is a difference in how many people develop pancreatic cancer over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Exenatide (also known as Byetta, Bydureon/Bydureon BCise)
What this could lead to: If this study finds no increased risk, it could provide reassurance about the long-term safety of exenatide for diabetes patients.
What could go wrong: This is an observational study, not a controlled trial, so it can only show links, not cause and effect. Results may be influenced by other factors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic neoplasm type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

Research Site
RECRUITING

Copenhagen, Denmark
Research Site
RECRUITING

Helsinki, Finland
Research Site
RECRUITING

Paris, France
Research Site
RECRUITING

Bergen, Norway
Research Site
RECRUITING

Barcelona, Spain
Research Site
RECRUITING

Vänersborg, Sweden
Research Site
RECRUITING

Edinburgh, United Kingdom
Research Site
RECRUITING

London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.